Telavancin
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Telavancin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Telavancin (trade name Vibativ) is a bactericidal lipoglycopeptide for use in MRSA or other Gram-positive infections. Telavancin is a semi-synthetic derivative of vancomycin.[1][2]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Vibativ |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610004 |
License data |
|
Routes of administration | intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 90%, mostly to albumin |
Elimination half-life | 9 hours |
Excretion | 76% in urine, <1% in feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.106.567 |
Chemical and physical data | |
Formula | C80H106Cl2N11O27P |
Molar mass | 1755.65 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
The FDA approved the drug in September 2009 for complicated skin and skin structure infections (cSSSI),[3] and in June 2013 for hospital-acquired and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus.[4]